MorphoSys Acquires Lanthipeptide Technology from Lanthio

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma

MARTINSRIED/MUNICH, Germany, Oct. 15, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Lanthio Pharma today announced the acquisition of Lanthio Pharma's lanthipeptide technology, which will be used for drug discovery by MorphoSys. The acquisition was triggered by MorphoSys exercising an option within an ongoing collaboration and option agreement between the two companies. By exercising the option, MorphoSys takes over the lanthipeptide technology and all related intellectual property. Lanthio Pharma will continue to focus on building its portfolio of selected lanthipeptide drugs and will participate financially in MorphoSys's exploitation of the technology. Financial details were not disclosed.

"Lanthipeptides can become a complementary addition to our therapeutic antibody pipeline and will add more diversity to our drug discovery and development approaches," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "The decision to acquire this technology was made following a feasibility study to establish high quality and diverse lanthipeptide-based libraries. This brings us closer to adding members of this class of stabilized peptides to our drug portfolio."

As part of its innovation capital initiative, MorphoSys entered a collaboration and option agreement with Lanthio Pharma in November 2012, which included an equity investment as part of the company's Series A financing round.

"Today's news marks an important step for our innovation capital initiative. The joint collaboration on a broader lanthipeptide platform has opened up an interesting opportunity to create further value for both MorphoSys and our partner," commented Jens Holstein, Chief Financial Officer of MorphoSys. "We will continue with this initiative and will seek other opportunities to invest and collaborate selectively with start-ups and smaller biotechs."

Dr. Gert Moll, Chief Scientific Officer of Lanthio Pharma commented: "Great synergies between our companies have resulted in a very successful collaboration. We are confident that MorphoSys will be able to further exploit the great potential of our technology platform by bringing more lanthipeptide drugs into the clinic."

Lanthipeptides comprise a novel class of therapeutics with high target selectivity and improved drug-like properties. Lanthio Pharma's approach can be used to identify peptides which are selective for a specific disease target and to stabilize them in their optimal structural conformation for receptor binding. The high specificity can open up new therapeutic applications, potentially providing drugs for indications classically not targeted with antibodies. In addition to intravenous administration, therapeutic plasma levels of lanthipeptides can potentially be achieved via oral, pulmonary or subcutaneous delivery.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com .

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

About Lanthio Pharma:

Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide technology to the discovery of novel peptide therapeutics with longer half-life and high receptor selectivity.

Lanthio Pharma is building a pipeline of therapeutic lanthipeptide drugs against diseases of high medical interest, including fibrosis, cardiovascular diseases, multiple sclerosis and cancer.

Constrained peptides like lanthipeptides are an emerging compound class which offers the potential to address many types of target and disease categories, currently beyond reach for therapeutic proteins or small molecules. The technology of Lanthio Pharma includes a proprietary bacterial display library capability, which allows construction of focused or randomized libraries of lanthipeptides that can be screened against disease targets of interest. MorphoSys AG has obtained the rights to commercialize Lanthio's technology.

Lanthio Pharma is funded by Inkef Capital, BioGeneration Ventures, MorphoSys and RUG Holding.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Lanthio Pharma
Michiel Lodder, PhD
VP Business Development
Tel: +31 (0)6 50 21 1329
lodder@lanthiopharma.com

Media Release (PDF) http://hugin.info/130295/R/1862848/653606.pdf

HUG#1862848

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 147

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 114

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 38

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 237

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 60

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading

Top 5 Most Recently Viewed Articles

B. Riley Financial Partners with Oaktree to Enhance Services

Updated Category News Views 55

B. Riley Financial and Oaktree: A Strategic Collaboration B. Riley Financial, Inc. (NASDAQ: RILY) is thrilled to announce a new partnership with Oaktree Capital Management, L.P. to strengthen its Great American Group businesses. Definitive Agreement Signed The companies have finalized a definitive agreement enabling a collaboration through a newly formed holding company...

Continue Reading
General Motors Faces Changes: A Shift in EV Incentive Strategy

Updated Category News Views 348

General Motors Adjusts EV Incentives General Motors Co. (NYSE: GM) has decided to revise its plans concerning electric vehicle (EV) incentives after initially suggesting options beyond the Federal EV Credit deadline. This shift comes shortly after rising scrutiny from political figures around the implications of such financial strategies. Concerns Raised by Key...

Continue Reading
Pacsun Unveils Stylish New Sunglasses Collection for All

Updated Category News Views 327

Pacsun Launches an Elegant Sunglass Collection Pacsun has taken a bold step in expanding its product range by introducing a new collection of premium sunglasses. This unisex line represents the brand's commitment to elevating its accessory offerings, appealing to a broader audience of style-conscious consumers. Innovative Designs in Sunglass Fashion With the release of...

Continue Reading
Exploring the Rapid Growth of the Opioid Use Disorder Market

Updated Category News Views 216

Understanding the Opioid Use Disorder Market and Its Promising Growth The opioid crisis represents a major public health challenge, significantly impacting communities across the globe. According to research, the Opioid Use Disorder Market was evaluated at approximately USD 3.7 billion recently, with an exciting projection to surge to USD 9.02 billion by 2032. This...

Continue Reading
Artea Bankas Secures ECB Approval for Stock Buyback Initiative

Updated Category News Views 242

Artea Bankas Secures ECB Approval for Stock Buyback Initiative AB Artea Bankas has recently gained essential approval from the European Central Bank (ECB) allowing the bank to buy back up to 4,500,000 of its own shares, marking a significant step in enhancing shareholder value. This buyback program is anticipated to commence within one year, demonstrating the bank's...

Continue Reading